Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Choosing zero based budgeting means every dollar has a purpose, reducing waste and improving long-term planning compared with traditional budgets.
24,393 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Backyard barbecues for 10 people now average $161, according to a Wells Fargo report. Hamburger beef leads price hike...
Ethereum is weighing a protocol-level shift that could divert staking rewards toward ecosystem development. The plan ...
David Tepper accelerates a $400 million macro bet pairing a country ETF with a memory-chip giant, underscoring what s...
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
As AI reshapes computing, three chip giants still worth buying offer a compelling setup for long-term investors. Expl...
Through the first half of 2026, mega funds over $1B captured about 72% of all VC capital raised, while first-time man...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Three legacy tech giants are pushing new strategies in 2026 as investors weigh durable enterprise moats against consu...
A single industrial stock riding infrastructure gains from the AI data-center buildout. Learn how to spot durable dem...
New projections warn the Social Security trust fund could exhaust by 2032, risking benefit cuts unless Congress acts....